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Abstract 
A new class of nucleoside analogues were synthesized using cyclic dipeptides and 
modified 2’-deoxyfuranoribose sugars to introduce flexibility by peptides in place of 
common nucleoside bases and to determine their biological properties. The synthesis 
was carried out by coupling of a protected ribose sugar with synthesized dipeptides in 
the presence of hexamethyldisilazane and trimethylsilyltriflate. The final products were 
characterized by NMR and high resolution MS-TOF spectroscopy. The compounds 
were evaluated for anti-HIV activities. 1-(4-Azido-5-(hydroxymethyl)tetrahydrofuran-2-
yl)-3,6-diisopropylpiperazine-2,5-dione (compound 14) containing 3- and 6-isopropyl 
groups in the base and 3’-azide (EC50 = 1.96 µM) was the most potent compound 
among all the synthesized analogs. 
 
 
 
 
 
Keywords: Anti-HIV, Carbopeptides, Cyclodipeptide, Nucleoside analogues, 2’-
Deoxyribofuranosyl  
 
  
Abbreviations: DCM (Dichloromethane), HMDS (Hexamethyldisilazane), TMSOTf 
(Trimethylsilyl triflate). 
  
Introduction 
 Nucleoside drugs are modified analogues of naturally occurring nucleosides, 
pyrimidines and purines1-3 that have found wide applications in anti-cancer and anti-HIV 
therapy.4-7 As an example, cytarabine (ara-C, Figure 1) is a pyrimidine analogue 
containing an arabinose sugar and has been used in the treatment of different cancers, 
such as acute myelogenous leukemia (AML) and non-Hodgkin’s lymphoma (NHL), 
chronic myelocytic leukemia (blast phase), acute lymphoblastic leukemia(ALL) and 
erythroleukemia.8-9 Other modified pyrimidine analogues drugs such as lamivudine 
(2′,3′-dideoxy-3′-thiacytidine,3TC) and emtricitabine (5-fluoro-2′,3′-dideoxy-3′-
thiacytidine, FTC) (Figure 1) have also found extensive use in anti-HIV therapy.10-11 
The modified nucleoside analogues have been designed to introduce functional 
groups or alterations in either sugar, base, or both parts.12 For example, zidovudine 
(AZT) (Figure 1), a modified thymidine analogue commonly used in anti-HIV therapy, 
has an azide (-N3) in place of 3-hydroxyl (-OH) group of thymidine sugar.4 Similarly, 
3TC and FTC derivatives have sulfur at 3-position of sugar while FTC also has a 
fluorine at C5 position of the base.13 Mechanism of activity of modified nucleoside 
generally involves binding on growing DNA/RNA, inhibition of DNA/RNA synthesis by 
chain termination, and/or interacting with enzymes in the process.14 
  
 
Figure 1. Chemical structures of AZT, FTC, 3TC and Cytarabine. 
 
 Herein, we report the synthesis of a new class of modified nucleosides by 
introducing a cyclic-dipeptide15-16 at the C-1 position of 2’-deoxyfuranoribose . The cyclic 
dipeptides containing two amide groups were designed as a six membered ring similar 
to a pyrimidine base. The double bond of the pyrimidine base17 was removed to 
generate more flexibility in the base structure. 
Results and Discussion 
Three commercial available cyclic dipeptides,18 diketopiperazine, 
dimethyldiketopiperazine, and diisopropyldiketopiperazine were used as building blocks 
for conjugation with protected carbohydrates. The protected 2’-deoxyfuranoribose 
methoxide or halides were synthesized according to the previously reported 
procedures.19 The ditoluoyl2’-deoxyfuranoribose chloride (1) was synthesized by 
  
protection of 2’-deoxyfuranoribosemethoxide followed by chlorination with dry HCl. The 
benzyloyl protected azido-2′-deoxyribosemethoxide(2) was synthesized from D-xylose 
(Supporting information). 
 Scheme 1. Chemical synthesis of 2’-deoxyribofuranosylcyclodipeptides. 
 
 Previous reports have shown that cyclodipeptide can react with alkyl halides 
using various mild to strong bases.20-21 Similar coupling/substitution reactions were 
used with protected sugar chloride using different bases viz. sodium hydride (NaH), 1,8-
diazabicyclo[5.4.0]undec-7-ene(DBU),22 butyl lithium, sodium methoxide, sodium 
hydroxide, and potassium hydroxide, but these methods were unsuccessful for the 
synthesis of desired products. In most of the cases, degraded sticky mixture of 
undesired products was obtained. In the case of reaction performed using NaH showed 
the presence of a negligible amount of desired product along with a number of different 
  
undesired products as shown by mass spectrometry of crude reaction mixture  but we 
were unable to isolate the product. The reaction performed using DBU as a base led to 
conjugation of DBU to sugar (DBU-sugar product) instead of formation of desired 
peptide-sugar product (data not shown). 
Alternatively, the cyclodipeptide was reacted with hexamethyldisilane23 in 
dioxane with refluxing to form bis-trimethanesilanyl cyclopeptide, which was 
subsequently coupled with carbohydrate chloride (1) and carbohydrate methoxide (2).24-
25 Subsequent complex was cleaved/deprotected using trimethylsilyl(TMS)-triflate to the 
desired protected carbohydrate-cyclopeptide products (3-8) in a mixture of - isomers. 
Finally, the sugar protecting groups (toluolyl or benzoyl) were removed in the presence 
of methanolic ammonia solution (7% w/v) to generate 2′-deoxyribofuranose-
cyclodipeptide products 9-14. The final products were purified by HPLC using the 
protocol described in the experimental section. The final product was identified by 1D, 
2D NMR spectroscopy and high resolution MS-TOF spectroscopy. 
All the synthesized compounds were evaluated for their inhibitory activity of HIV–
1 (subtype B, US/92/727) replication in human peripheral blood mononuclear (PBMC) 
cells.26 Table 1 illustrates the anti-HIV-1 activity (EC50) and cytotoxicity (TC50) of the 
nucleoside ester conjugates compared with AZT. No cytotoxicity was observed up to the 
highest tested concentration for the synthesized conjugates 9-14 (TC50100 µM) (1-7). 
 
 
 
  
Table 1. Inhibition of HIV-1 subtype B (US/92/727) replication in Human PBMC cells. 
 
Compound EC50 (µM)a TC50 (µM)b TI (µM)c 
9 72.3 >100.0 >1.38 
10 27.6 >100.0 >3.62 
11 74.5 >100.0 >1.34 
12 89.5 >100.0 >1.12 
13 13.7 >100.0 >7.30 
14 1.96 >100.0 >51.02 
AZT 0.001 >1.0 >1000.0 
aEC50 (50% effective concentration), All the assays were carried out in triplicate (n = 3); 
bTC50 (50% toxic concentration), All the assays were carried out in triplicate (n = 3); 
cTherapeutic index (TC50/EC50). 
 
All the conjugates (9-14, EC50 = 1.96-89.5µM) exhibited consistently less anti-HIV 
activity than that of AZT (EC50 = 0.001µM), indicating that the planar structure of the 
base is critical for maximum anti-HIV activity. Compounds 9-14 contain a flexible CHR3 
groups at positions 3 and 6 while AZT has a rigid 5-6 alkene and an amide group at 
  
positions 3-4. Rigidity and aromaticity of the base appear to be important in generating 
optimal anti-HIV activity. 
Compound 14 containing 3- and 6-isopropyl groups in the base and 3′-azide 
(EC50 = 1.96 µM) was the most potent compound among all the synthesized analogs. 3′-
Azido analog 13 with a 3,6-methyl substituent at the base also showed modest anti-HIV 
activity (EC50 -= 13.7 µM).  
The anti-proliferative activity of the synthesized derivatives was evaluated in 
human leukemia (CCRF-CEM), ovarian adenocarcinoma (SK-OV-3), colorectal 
carcinoma (HT-29), and breast carcinoma (MDA-MB-468) cells. Doxorubicin was used 
as the positive control.27-28 The 2′-deoxyribofuranose-cyclodipeptide products did not 
exhibit any significant anti-proliferative activity in all cancer cell lines at the 
concentration of 50 µM and up to the incubation period of 96 h. Compound 14 showed 
nearly 20-25% anti-proliferative activity after 120h of incubation with MDA-MB-468 cells. 
(detailed activity in supporting information). 
 
Conclusions 
In conclusion, novel six 2’-deoxyribofuranosyl cyclodipeptides were synthesized 
and characterized by using NMR and mass spectroscopy. The synthesized derivatives 
were evaluated for their anti-HIV activity. The compounds exhibited inferior  anti-HIV 
activity than AZT. The data indicate that the loss of planarity (aromaticity) of base 
moiety in the structures is detrimental in biological activity of these compounds. On the 
  
other hand, incorporation of more lipophilic alkyl groups at positions 3 and 6 of the base 
in 3′-azido analogs generated compounds with modest anti-HIV activity. 
 
 
Experimental Protocols 
Materials and methods. Cyclodipeptides were purchased from Chem-Impex 
International, Wood dale, IL, USA. Anhydrous solvents and other chemicals and reagents 
were purchased from Sigma-Aldrich Chemical Co. (Milwaukee, WI). The chemical 
structures of final products were characterized by nuclear magnetic resonance spectra 
(1H NMR, 13C NMR) obtained on a Bruker NMR spectrometer (400 MHz) or a Varian NMR 
spectrometer (500 MHz). 13C NMR spectra are fully decoupled. Chemical shifts were 
reported in parts per millions (ppm) using deuterated solvent peak or tetramethylsilane 
(internal) as a standard. The chemical structures of final products were confirmed by a 
high-resolution Biosystems QStar Elite time-of-flight electrospray mass spectrometer. 
Details of synthetic procedures and spectroscopic data of the respective compounds are 
presented below. Final compounds were purified on a Phenomenex Prodigy 10 μm ODS 
reversed-phase column (2.1 cm × 25 cm) with a Hitachi HPLC system using a gradient 
system of acetonitrile or methanol and water (CH3CN/CH3OH/H2O, 0−100%, pH 7.0, 60 
min).  
 
  
5-(2,5-Doxopiperazin-1-yl)-2-(((4-methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-
methylbenzoate (3). Diketopiperazine (5 mg, 0.04 mmol), hexamethyldisilane(HMDS) 
(12 mg, 0.08 mmol), and (NH4)2SO4 (2 mg) were mixed in dry dioxane (7 mL) under 
nitrogen atmosphere and refluxed for 4 h. The reaction mixture was brought to room 
temperature. 2’-deoxyribofuranosylchloride(1, 16 mg, 0.04 mmol) was added and the 
solution was stirred at room temperature for 10 min followed by heating at 80C for 6h. 
The reaction mixture was ice cooled. TMSOTf (18 mg, 0.08 mmol) was added dropwise 
to the solution, and the reaction mixture was allowed to stir at room temperature for 10 
h. The reaction mixture was neutralized with excess of a dilute solution of NaHCO3 and 
extracted with CH2Cl2 (3 × 30 mL). The crude product was concentrated and purified on 
silica flash chromatography using hexane and ethyl acetate (0-10%, v/v) as the eluent 
solvent. The product was further purified on reverse phase HPLC eluted with water and 
acetonitrile as the eluents. Yield: 11 mg, 55%. (α:β: 2:3 from NMR), 1H NMR (500 MHz, 
CDCl3) δ ppm 7.88-7.97 (m, 4 H, Ar-o-H), 7.21-7.30 (m, 4 H, Ar-m-H), 7.06 (s, 1 H, NH), 
6.48-6.57 (m, 1 H, C1′H), 5.50-5.60 (m, 1 H, C4′H), 4.72 (s, 1/2 H, C3′H), 4.55-4.65 (m, 
1 H, C5′H), 4.49-4.53 (m, 1 H, C5′H), 4.42 (s, 1/2 H, C3′H), 4.20-4.30 (m, 1/2 H, C6-H), 
4.11-4.18 (m, 1 H, C6-H), 4.00-4.07 (m, 2 H, C3-H),3.90-3.92 (m, 1/2 H, C6-H), 2.87-
2.97 (m, 1/2 H, C2′H), 2.36-2.44 (m, 6 H, 2 × CH3), 2.29-2.35 (m, 1 H, C2′H), 2.18-2.25 
(m, 1/2 H, C2′H);13CNMR (125MHz, CDCl3) δ ppm: 166.30, 166.23 (CO), 166.02, 
165.96 (CO), 164.32, 163.85 (CO), 144.47, 144.24 (CO-C-Ar), 129.82, 129.70 (Ar-o-C), 
129.44, 129.35 (Ar-m-C), 129.32, 129.26 (Ar′-m-C),84.41 (α3′), 83.56 (β3′) 82.79 (α1′), 
81.57 (β1′), 74.98 (α4′), 74.58 (β4′), 64.54 (α5′), 64.03 (β5′), 45.43 (3COCH2),  43.46 (α 
  
6COCH2), 42.95 (β 6COCH2), 36.47 (α2′), 33.68 (β2′), 21.75, 21.73 (Ar-CH3). HRMS 
(ESI-TOF): calcd: 466.1740 for C25H26N2O7, found: 467.1662 [M+H]+. 
 
1-(4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-piperazine-2,5-dione (9). 
Compound 3 (10 mg, 0.02 mmol) was stirred with methanolic ammonium solution (7%, 
10 mL) at room temperature for 30 min. The solvent was evaporated under reduced 
pressure, and the crude product was purified on flash chromatography using 
CHCl3/methanol (0-100%, v/v) eluent. The product was further purified on a reverse 
phase HPLC using water:methanol eluents (3 mg, 62% yield). 1H NMR (500 MHz, 
Methanol-d3) δ ppm 6.06-6.17 (m, 1 H, C1′H), 5.69 - 5.79 (m, 1 H, C4′H), 4.00-4.27 (m, 
3H,  C5′H, C3′H), 3.88-3.94 (m, 1 H, C6-H), 3.35-3.66 (m, 3 H, C3-H, C6-H), 2.59-2.78 
(m, 1/2 H, C2′H), 1.92-2.51 (m, 1/2 H, C2′H), 1.73-1.89 (m, 1 H, C2′H).HRMS (ESI-
TOF): calcd.: 230.0903 for C9H14N2O5, found: 231.1032 [M+H]+. 
 
5-(2,5-Dimethyl-3,6-dioxopiperazin-1-yl)-2-(((4-methylbenzoyl)oxy)methyl) 
tetrahydrofuran-3-yl 4-methylbenzoate (4).Compound 4 was synthesized from 
dimethyldiketopiperazine(6 mg, 0.04 mmol) and sugar chloride 1(16 mg, 0.04 mmol) by 
following the procedure similar to the synthesis of 3 (10 mg, 48% yield). HRMS (ESI-
TOF): cacld: 494.2053 for C27H30N2O7, found: 495.2198 [M+H]+, 517.2039 [M+Na]+. 
 
  
1-(4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6-dimethylpiperazine-2,5-
dione (10). Compound 4(8 mg, 0.016 mmol) was hydrolyzed with methanolic ammonia 
solution and purified by flash chromatography and reverse phase HPLC (2.5 mg, 61% 
yield).  HRMS (ESI-TOF): calcd: 258.1216 for C11H18N2O5, found: 259.1095 [M+H]+. 
 
5-(2,5-Diisopropyl-3,6-dioxopiperazin-1-yl)-2-(((4-
methylbenzoyl)oxy)methyl)tetrahydrofuran-3-yl 4-methylbenzoate(5). Compound 5 
was synthesized from the reaction of diisopropyldiketopiperazine(8 mg, 0.04 mmol) with 
sugar chloride1 (16 mg, 0.04 mmol) by following the procedure similar to the synthesis 
of 3 (14 mg, 63% yield). 1H NMR (500 MHz, CDCl3) δ ppm 7.82-7.96 (m, 4 H, Ar-o-H), 
7.23-7.32 (m, 4 H, Ar-m-H), 6.51-6.58 (m, 1 H, C1′H), 5.49-5.57 (m, 1 H, C4′H), 4.70-
4.76 (m, 1 H, C4′H), 4.57-4.66 (m, 2 H, C5′H), 4.50-4.54 (m, 1 H, C3′H), 4.20-4.30 (m, 1 
H, C6-H), 4.09-4.18 (m, 2 H, C3-H), 4.00-4.07 (m, 2 H, isopr C3′′-H), 2.87-2.97 (m, 1/2 
H, C2′H), 2.36-2.44 (m, 6 H, 2 × CH3), 2.29-2.35 (m, 1 H, C2′H), 2.18-2.25 (m, 1/2 H, 
C2′H), 0.92-1.09 (m, 12H, 4 × CH3).13CNMR (125MHz, CDCl3) δppm:166.30, 166.23 
(CO), 166.02, 165.96 (CO), 164.32, 163.85 (CO), 144.47, 144.24 (CO-C-Ar), 129.82, 
129.70 (Ar-o-C), 129.44, 129.35 (Ar-m-C), 129.32, 129.26 (Ar′-m-C), 84.41 (α3′), 83.56 
(β3′), 82.79 (α1′), 81.57 (β1′), 74.98 (4′), 64.54 (5′), 45.43 (3COCH), 43.46 (6COCH), 
30.99 (2′), 21.70 (Ar-CH3), 18.85 (isopr C3′′),16.37 (isopr CH3).HRMS (ESI-TOF): calcd: 
550.2679 for C31H38N2O7, found: 573.0976 [M+Na]+. 
 
  
1-(4-Hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6-diisopropylpiperazine-
2,5-dione (11). Compound 5 (10 mg, 0.018 mmol) was hydrolyzed with methanolic 
ammonia solution (2 mL of 7% sol) and was purified by flash chromatography and 
reverse phase HPLC (yield 2.5 mg, 45%). MS (ESI-TOF): calcd: 314.1842 for 
C15H26N2O5, found: 315.5 [M+H]+. 
 
(3-Azido-5-(2,5-dioxopiperazin-1-yl)tetrahydrofuran-2-yl)methyl benzoate (6). 
Compound 6 was synthesized from the reaction of diketopiperazine(5 mg, 0.04 mmol) 
with azido-sugar methoxide 2 (11 mg, 0.04 mmol) by following the procedure similar to 
the synthesis of 3 (9 mg, 58 % yield)(α:β: 35:65 from 13C NMR). 1H NMR (400 MHz, 
CDCl3) δ ppm 8.04 (d, J = 8Hz, 2H, Ar-o-H), 7.60 (t, J = 8Hz, 1H, Ar-p-H), 7.49 (t, J = 
8Hz, 2H, Ar-m-H), 7.11 (s, 1 H, NH), 6.33 - 6.42 (m, 1 H, C1′H), 4.52 (br s, 1 H, C4′H), 
4.34-4.47 (m, 2 H, C5′H), 3.97-4.12 (m, 4H, C6-H, C3-H), 2.65-2.77 (m, 1 H, C3′H), 
2.23-2.31 (m, 1 H, C2′H), 2.00-2.11 (m, 1H, C2′H).13CNMR (100MHz, CDCl3) δ ppm:  
166.76, 166.36 (CO), 164.35, 163.16 (CO), 133.61 (Ar-C4), 129.75 (Ar-C2), 128.72 
(ArC1), 128.68 (Ar-C3), 83.72 (3′), 82.41 (α1′), 82.33 (β1′), 80.79 (4′), 64.23 (5′), 45.46 
(C3CH2), 43.62 (α C6CH2), 43.49 (β  C6CH2), 35.61 (β2′), 33.90 (α2′). HRMS (ESI-
TOF): calcd: 359.123 for C16H17N5O5, found: 360.0913 [M+H]+. 
 
1-(4-Azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-piperazine-2,5-dione (12). 
Compound 4(7 mg, 0.019 mmol) was hydrolyzed with methanolic ammonia solution (3 
mL of 7% sol) and purified by flash chromatography and reverse phase HPLC (yield 2.6 
  
mg, 52%). 1H NMR (400 MHz, CD3OD) δ ppm 7.99 (s, 1H, NH), 6.24-6.31 (m, 1 H, 
C1′H), 4.24-4.32 (m, 1/2 H, C4′H), 4.09-4.14 (m, 1/2 H, C4′H),3.92-3.99 (m, 1 H, C3′H), 
3.55-3.69 (m, 2 H, C5′H), 3.01 (s, 2H, C6-H), 2.88 (s, 2H, C3-H), 2.61-2.74 (m, 1 H, 
C2′H), 1.99-2.09(m, 1 H, C2′H). 13CNMR (100MHz, CD3OD) δ ppm: 165.67 (CO), 85.30 
(1′), 83.76 (3′), 82.33 (4′), 61.82 (5′), 44.69 (C3 CH2), 43.09(C6 CH2), 34.93 (2′). HRMS 
(ESI-TOF): cacld: 255.0968 for C9H13N5O4, found: 278.0526 [M+Na]+. 
 
(3-Azido-5-(2,5-dimethyl-3,6-dioxopiperazin-1-yl)tetrahydrofuran-2-yl)methyl 
benzoate (7).Compound 7 was synthesized from the reaction of 
dimethyldiketopiperazine (6 mg, 0.04 mmol) with azido-sugar methoxide2(11 mg, 0.04 
mmol) by following the procedure similar to the synthesis of 3 (8 mg, 48 % yield). 1H 
NMR (400 MHz, CDCl3) δ ppm 8.01 (d, J = 4Hz, 2H, Ar-o-H),7.82 (s, 1 H, NH), 7.58 (t, J 
= 4Hz, 1H, Ar-p-H), 7.46 (t, J = 4Hz, 2H, Ar-m-H), 6.03 - 6.12 (m, 1 H, C1′H), 4.35-4.45 
(m, 3 H, C4′H, C5′H), 4.03-4.22 (m, 3H, C6-H, C3-H, C3′H), 2.67-2.78 (m, 1 H, C2′H), 
2.20-2.34 (m, 1H, C2′H), 1.61 (d, J = 8Hz, 3H, CH3), 1.54 (d, J = 8Hz, 3H, CH3). 
13CNMR (100MHz, CDCl3) δ ppm:  170.29, 167.90, 166.19 (CO), 133.57 (Ar-C4), 
129.70 (Ar-C2), 129.30 (ArC1), 128.66 (Ar-C3), 86.28 (1′), 82.63 (4′), 64.21 (5′), 61.18, 
52.59 (C3 CH), 51.95 (C6 CH), 37.04 (2′), 22.56 (C3 CH3), 21.71 (C6 CH3). HRMS (ESI-
TOF): calcd: 387.1543 for C18H21N5O5, found: 410.1029 [M+Na]+. 
 
1-(4-Azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6-dimethylpiperazine-2,5-
dione (13).Compound 7(5 mg, 0.013 mmol) was hydrolyzed with methanolic ammonia 
  
solution (3 mL of 7% sol) and purified by flash chromatography and reverse phase 
HPLC (1.5 mg, 42%). 1H NMR (400 MHz, CD3OD) δ ppm 7.87 (s, 1 H, NH), 5.93-6.14 
(m, 1 H, C1′H), 3.94-4.33 (m, 4 H, C4′H, C3′H, C6-H, C3-H), 3.61 (s, 2H, C5′H), 2.60-
2.74 (m, 1 H, C2′H), 2.02-2.27 (m, 1H, C2′H), 1.60 (d, J = 4Hz, 3H, CH3), 1.51 (d, J = 
4Hz, 3H, CH3). 13CNMR (100MHz, CD3OD) δ ppm: 168.86, 168.52, (CO), 86.71 (1′), 
86.21 (4′), 85.96 (3′), 61.88 (5′), 61.01, 52.46 (C3 CH), 51.55 (C6 CH), 36.62 (2′), 21.43, 
20.32 (C3 CH3), 17.73, 15.64 (C6 CH3). HRMS (ESI-TOF): calcd: 283.1281 for 
C11H17N5O4, found: 284.0849 [M+H]+. 
 
(3-Azido-5-(2,5-diisopropyl-3,6-dioxopiperazin-1-yl)tetrahydrofuran-2-yl)methyl 
benzoate (8). Compound 8 was synthesized from the reaction of 
diisopropyldiketopiperazine(8 mg, 0.04 mmol) with azido-sugar methoxide2(11 mg, 0.04 
mmol) by following the procedure similar to the synthesis of 3(9.5 mg, 54% yield). 1H 
NMR (400 MHz, CDCl3) δ ppm 7.98-8.17 (m, 2H, Ar-o-H),7.38-7.66(m, 3H, Ar-p-H, Ar-
m-H), 6.39-6.49 (m, 1 H, C1′H), 5.31 (s, 1H, C4′H), 4.35-4.58 (m, 2 H, C5′H), 4.07-4.32 
(m, 1H, C6-H), 3.58-3.88 (m, 1H, C3-H), 3.26-3.88 (br s, 1H,C3′H), 2.49-2.86 (m, 1 H, 
C2′H), 1.78-2.48 (m, 3H, C2′H, 2 × isopr CH), 0.94-1.24 (br s,12H, 4 × isopr CH3). 
13CNMR (100MHz, CDCl3) δ ppm:  168.96, 166.17 (CO), 133.51 (Ar-C4), 129.81 (Ar-
C2), 129.75 (ArC1), 128.61 (Ar-C3), 88.86 (1′), 82.90 (4′), 64.13 (5′), 62.95, 62.25 (C3 
CH), 60.97 (C6 CH), 37.17 (2′), 34.59, 32.79 (isopr CH),20.10, 19.93, 19.46, 19.31 
(isopr 4 × CH3). HRMS (ESI-TOF): calcd: 443.2169 for C22H29N5O5 found: 444.1338 
[M+H]+. 
  
 
1-(4-Azido-5-(hydroxymethyl)tetrahydrofuran-2-yl)-3,6-diisopropylpiperazine-2,5-
dione (14).Compound 4(5 mg, 0.011 mmol) was hydrolyzed with methanolic ammonia 
solution (2 mL of 7% sol) and purified by flash chromatography and reverse phase 
HPLC. 1H NMR (400 MHz, CD3OD) δ ppm 5.69–5.77 (m, 1 H, C1′H), 4.15-4.28 (m, 2H, 
C4′H, C3′H), 3.76 (d, J = 8 Hz, 1H, C6H), 3.60 (s, 2H, C5′H), 3.46 (d, J = 8Hz, 1H, 
C3H), 2.57-2.68 (m, 1 H, C2′H), 2.35-2.45 (m, 1H, C2′H), 1.97-2.12 (br s, 2H, 2 × isopr 
CH), 0.97-1.17 (m, 12H, 4 × isopr CH3). 13CNMR (100MHz, CD3OD) δ ppm: 170.25, 
167.85(CO), 88.99 (C1′), 86.64 (C4′), 62.40 (C5′), 62.29, 61.86 (C3 CH), 60.84 (C6 CH), 
36.64 (C2′), 34.61 (isopr CH), 33.35 (isopr CH),19.12, 18.99, 18.78 (isoprCH3). HRMS 
(ESI-TOF): calcd: 339.1907 for C15H25N5O4, found: 340.1554 [M+H]+. 
 
 
Anti-HIV-1 Evaluation in PMBC Assay. PBMC based anti-HIV assays were performed 
as previously described.26 Briefly, PHA-stimulated PBMCs cultured in the presence of 
IL-2 were suspended at 1 × 106 cells/mL and were added to a 96-well round-bottom 
plate. Serially diluted test materials were added to the plate in triplicate followed by the 
appropriate pre-titered strain of HIV. The culture was incubated for 7 days at 37 °C/5% 
CO2. Following the incubation, supernatants were collected for analysis of virus 
replication by supernatant RT activity and cells analyzed for viability by XTT dye 
reduction. AZT was used as an internal assay standard. All the assays were carried out 
in triplicate. 
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